Real-life Study of the Efficacy of Management of Migraine Patients After Failure of 2 Prophylactic Treatments (EVIREMIG)

Centre Hospitalier Régional Metz-Thionville

Status: Completed

Conditions: Migraine

Treatments: Behavioral: Patient health care observational follow up after 2 prophylactic tratments

Study type: Observational

Funder types: Other

Identifiers

NCT05947123

2023-07Obs-CHRMT

Details and patient eligibility

About

This is a real-life, observational, single-center cohort study to describe the efficacy of prophylactic treatment in patients after failure of at least 2 prophylactic treatments. Patients included in the study will be followed up in consultations or day hospitals according to their usual care, and will be asked to complete the MIgraine Disability Assessment (MIDAS), Headache Impact Test short-form (HIT-6), Patient Global Impression of Change (PGIC), Hospital Anxiety and Depression (HAD) scale and Work and Personal Activities Impairment (WPAI) questionnaires at each visit.

Data describing their care will be extracted from computerized patient records.

Enrollment: 127 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Migraine [International Headache Society (IHS) criteria 2013, revised 2018] with or without aura
• Monthly number of attacks ≥ 8 for at least 3 months
• Indication for prophylactic treatment
• For eptinezumab: resistance to at least 2 conventional disease-modifying therapies
• Agrees to use data for research purposes

Exclusion criteria

• Vascular history: myocardial infarction (MI), unstable angina or coronary bypass surgery, stroke or transient ischemic attack (TIA), Peripheral Arterial Disease of the Lower Limbs (PAD), uncontrolled hypertension

  • Need for analgesics for a cause other than migraine
  • Difficulty in understanding French language or cognitive impairment that compromises completion of self-questionnaires.